Tirzepatide induces a thermogenic-like amino acid signature in brown adipose tissue.


Journal

Molecular metabolism
ISSN: 2212-8778
Titre abrégé: Mol Metab
Pays: Germany
ID NLM: 101605730

Informations de publication

Date de publication:
10 2022
Historique:
received: 16 06 2022
revised: 12 07 2022
accepted: 13 07 2022
pubmed: 4 8 2022
medline: 15 9 2022
entrez: 3 8 2022
Statut: ppublish

Résumé

Tirzepatide, a dual GIP and GLP-1 receptor agonist, delivered superior glycemic control and weight loss compared to selective GLP-1 receptor (GLP-1R) agonism in patients with type 2 diabetes (T2D). These results have fueled mechanistic studies focused on understanding how tirzepatide achieves its therapeutic efficacy. Recently, we found that treatment with tirzepatide improves insulin sensitivity in humans with T2D and obese mice in concert with a reduction in circulating levels of branched-chain amino (BCAAs) and keto (BCKAs) acids, metabolites associated with development of systemic insulin resistance (IR) and T2D. Importantly, these systemic effects were found to be coupled to increased expression of BCAA catabolic genes in thermogenic brown adipose tissue (BAT) in mice. These findings led us to hypothesize that tirzepatide may lower circulating BCAAs/BCKAs by promoting their catabolism in BAT. To address this question, we utilized a murine model of diet-induced obesity and employed stable-isotope tracer studies in combination with metabolomic analyses in BAT and other tissues. Treatment with tirzepatide stimulated catabolism of BCAAs/BCKAs in BAT, as demonstrated by increased labeling of BCKA-derived metabolites, and increases in levels of byproducts of BCAA breakdown, including glutamate, alanine, and 3-hydroxyisobutyric acid (3-HIB). Further, chronic administration of tirzepatide increased levels of multiple amino acids in BAT that have previously been shown to be elevated in response to cold exposure. Finally, chronic treatment with tirzepatide led to a substantial increase in several TCA cycle intermediates (α-ketoglutarate, fumarate, and malate) in BAT. These findings suggest that tirzepatide induces a thermogenic-like amino acid profile in BAT, an effect that may account for reduced systemic levels of BCAAs in obese IR mice.

Identifiants

pubmed: 35921984
pii: S2212-8778(22)00119-3
doi: 10.1016/j.molmet.2022.101550
pmc: PMC9396640
pii:
doi:

Substances chimiques

Amino Acids, Branched-Chain 0
Glucagon-Like Peptide-1 Receptor 0
Gastric Inhibitory Polypeptide 59392-49-3
tirzepatide OYN3CCI6QE

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

101550

Informations de copyright

Copyright © 2022 The Author(s). Published by Elsevier GmbH.. All rights reserved.

Auteurs

Ricardo J Samms (RJ)

Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN, 46285, USA. Electronic address: samms_ricardo_j@lilly.com.

GuoFang Zhang (G)

Duke Molecular Physiology Institute and Sarah W. Stedman Nutrition and Metabolism Center, Duke University School of Medicine, Durham, NC, USA; Department of Medicine, Division of Endocrinology and Metabolism, Duke University School of Medicine, Durham, NC, USA.

Wentao He (W)

Duke Molecular Physiology Institute and Sarah W. Stedman Nutrition and Metabolism Center, Duke University School of Medicine, Durham, NC, USA.

Olga Ilkayeva (O)

Duke Molecular Physiology Institute and Sarah W. Stedman Nutrition and Metabolism Center, Duke University School of Medicine, Durham, NC, USA; Department of Medicine, Division of Endocrinology and Metabolism, Duke University School of Medicine, Durham, NC, USA.

Brian A Droz (BA)

Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN, 46285, USA.

Steven M Bauer (SM)

Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN, 46285, USA.

Cynthia Stutsman (C)

Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN, 46285, USA.

Valentina Pirro (V)

Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN, 46285, USA.

Kyla A Collins (KA)

Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN, 46285, USA.

Ellen C Furber (EC)

Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN, 46285, USA.

Tamer Coskun (T)

Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN, 46285, USA.

Kyle W Sloop (KW)

Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN, 46285, USA.

Joseph T Brozinick (JT)

Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN, 46285, USA.

Christopher B Newgard (CB)

Duke Molecular Physiology Institute and Sarah W. Stedman Nutrition and Metabolism Center, Duke University School of Medicine, Durham, NC, USA; Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC, USA; Department of Medicine, Division of Endocrinology and Metabolism, Duke University School of Medicine, Durham, NC, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH